RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the second quarter ended June 30, 2011 and other business updates. Total product revenue was $133.2 million for the second quarter of 2011, a 42% increase compared to $93.8 million for the second quarter of 2010. Total product revenue for the first six months of 2011 was $239.1 million, a 73% increase compared to $137.9 million for the first six months of 2010. XIFAXAN® revenue for the second quarter of 2011 was $87.0 million, a 20% increase compared to $72.4 million for the second quarter of 2010. XIFAXAN revenue for the first six months of 2011 was $167.7 million, a 64% increase compared to $102.3 million for the first six months of 2010. The $72.4 million XIFAXAN revenue for the second quarter of 2010 reflects product stocking during the quarter associated with the approval and launch of XIFAXAN 550 for hepatic encephalopathy.
